With the purchase of these assets, Roche Diagnostics will transfer the manufacturing capabilities for the above products to an inhouse manufacturing facility. According to Andreas Görtz, VP of Marketing at Roche NimbleGen, 'The acquired products are integral to the high quality data the NimbleGen array workflow provides researchers worldwide. Acquiring these assets will allow Roche complete control over the production, support and service of these products to ensure continued timely distribution, full support and the high level of service our customers have grown to expect from Roche."
For more information on Roche NimbleGen products, visit www.nimblegen.com